Wave Life Sciences Ltd.
WVEHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframePart of the healthcare sector, Wave Life Sciences Ltd. (WVE) is listed under Biotechnology. The company carries a $1.12B market cap, placing it firmly in the small-cap category. The company's medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Market Cap
$1.12B
Beta
-1.29
P/E (TTM)
—
P/E (Fwd)
-5.37
EPS (TTM)
$-1.05
EPS (Fwd)
$-1.08
ROE
-53.1%
ROA
-28.2%
Cash
$544.6M
Total Debt
$15.7M
Free CF
-$125.7M
52W Change
-30.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $544.6M in cash comfortably exceeding the $15.7M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$125.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -53.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $41.0M (2021) to $42.7M (2025).
The relatively low beta of -1.29 suggests WVE is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, WVE has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Wave Life Sciences Ltd. and its sector.